Indication
Severe recalcitrant psoriasis
Severe recalcitrant psoriasis is an advanced, treatment-resistant clinical state of psoriasis, a chronic immune-mediated inflammatory disorder primarily affecting the skin. Read more about Severe recalcitrant psoriasis
96 drugs 68 manufacturers
Drugs that treat it
Common Severe recalcitrant psoriasis therapies.
METHOTREXATE SODIUM (methotrexate sodium/PF)
METHOTREXATE (methotrexate sodium)
OXSORALEN-ULTRA (methoxsalen)
METHOTREXATE SODIUM (methotrexate sodium/PF)
METHOTREXATE (methotrexate sodium/PF)
REDITREX (PF) (methotrexate/PF)
RASUVO (PF) (methotrexate/PF)
JYLAMVO (methotrexate)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonSevere recalcitrant psoriasis is an advanced, treatment-resistant clinical state of psoriasis, a chronic immune-mediated inflammatory disorder primarily affecting the skin.
It is characterized by extensive epidermal involvement—frequently covering greater than 10% of body surface area or critically impairing high-impact functional areas—that has failed to respond adequately to standard modalities, including topical agents, phototherapy, and conventional systemic therapies.
Pathophysiologically driven by dysregulated T-cell activation and sustained pro-inflammatory cytokine signaling (notably TNF-alpha, IL-23, and IL-17), it manifests clinically as hyperkeratotic, erythematous plaques with thick silvery scales, prominent pruritus, and substantial physical disability.
- nih.gov
Severe recalcitrant psoriasis is an advanced, treatment-resistant clinical state of psoriasis, a chronic immune-mediated inflammatory disorder primarily affecting the skin Pathophysiologically driven by dysregulated T-cell activation and sustained pro-inflammatory cytokine signaling (notably TNF-alpha, IL-23, and IL-17), it manifests clinically as hyperkeratotic, erythematous plaques with thick silvery scales, prominent pruritus, and substantial physical disability
- fda.gov
Severe recalcitrant psoriasis is an advanced, treatment-resistant clinical state of psoriasis, a chronic immune-mediated inflammatory disorder primarily affecting the skin
- psoriasiscouncil.org
It is characterized by extensive epidermal involvement—frequently covering greater than 10% of body surface area or critically impairing high-impact functional areas—that has failed to respond adequately to standard modalities, including topical agents, phototherapy, and conventional systemic therapies
- webmd.com
It is characterized by extensive epidermal involvement—frequently covering greater than 10% of body surface area or critically impairing high-impact functional areas—that has failed to respond adequately to standard modalities, including topical agents, phototherapy, and conventional systemic therapies
- dermsquared.com
It is characterized by extensive epidermal involvement—frequently covering greater than 10% of body surface area or critically impairing high-impact functional areas—that has failed to respond adequately to standard modalities, including topical agents, phototherapy, and conventional systemic therapies Pathophysiologically driven by dysregulated T-cell activation and sustained pro-inflammatory cytokine signaling (notably TNF-alpha, IL-23, and IL-17), it manifests clinically as hyperkeratotic, er...
- nih.gov
Pathophysiologically driven by dysregulated T-cell activation and sustained pro-inflammatory cytokine signaling (notably TNF-alpha, IL-23, and IL-17), it manifests clinically as hyperkeratotic, erythematous plaques with thick silvery scales, prominent pruritus, and substantial physical disability
- nih.gov
Pathophysiologically driven by dysregulated T-cell activation and sustained pro-inflammatory cytokine signaling (notably TNF-alpha, IL-23, and IL-17), it manifests clinically as hyperkeratotic, erythematous plaques with thick silvery scales, prominent pruritus, and substantial physical disability
Personalize your experience
Follow Severe recalcitrant psoriasis and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.